{"id":"W4386784489","doi":"10.1158/1557-3265.aacrahns23-po-009","title":"Abstract PO-009: Phase 3 KEYNOTE-630 study of adjuvant pembrolizumab in high-risk locally advanced cutaneous squamous cell carcinoma","year":2023,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Nonmelanoma Skin Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Medicine; Perineural invasion; Pembrolizumab; Lymph node; Radiation therapy; Cancer; Surgery; Oncology; Pathology; Internal medicine; Immunotherapy","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001501733,0.001103993,0.001127385,0.0002673385,0.000377266,0.001130672,0.0007680701,0.001187432,0.007796839],"category_scores_gemma":[0.0007197929,0.0004020019,0.001044319,0.0003321413,0.0006126717,0.0007276405,0.000343446,0.003197599,0.001631696],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007967709,"about_ca_system_score_gemma":0.00166944,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001055815,"about_ca_topic_score_gemma":0.002478721,"domain_scores_codex":[0.9997805,0.00009339565,0.00001356554,0.00003540223,0.00002849694,0.00004869808],"domain_scores_gemma":[0.9996006,0.0000564666,0.00008735882,0.00003164162,0.00004000872,0.0001839216],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7114694,0.07415099,0.005802204,0.003104569,0.002043275,0.0004200662,0.0002850698,0.002817013,0.06357604,0.0006726436,0.01595362,0.1197051],"study_design_scores_gemma":[0.7808002,0.2008047,0.009053579,0.0001112143,0.0005571289,0.0002456066,0.00005942745,0.001007408,0.002836698,0.0003048399,0.004195564,0.00002369991],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9790396,0.004389219,0.0007836682,0.0009709856,0.0003055059,0.005555437,0.00282534,0.0002663664,0.005863759],"genre_scores_gemma":[0.9756905,0.003532328,0.001732079,0.002368478,0.0002248808,0.005192276,0.003792419,0.00005396908,0.007413093],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007796839,"threshold_uncertainty_score":0.02608305,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1278324920362891,"score_gpt":0.4910254474834192,"score_spread":0.36319295544713,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}